U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H22N2S
Molecular Weight 286.435
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THENALIDINE

SMILES

CN1CCC(CC1)N(CC2=CC=CS2)C3=CC=CC=C3

InChI

InChIKey=KLOHYVOVXOUKQI-UHFFFAOYSA-N
InChI=1S/C17H22N2S/c1-18-11-9-16(10-12-18)19(14-17-8-5-13-20-17)15-6-3-2-4-7-15/h2-8,13,16H,9-12,14H2,1H3

HIDE SMILES / InChI
Molecular Formula C17H22N2S
Molecular Weight 286.435
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.drugbank.ca/drugs/DB04826 http://www.un.org/esa/coordination/CL12.pdf

Thenalidine is an antihistamine with anticholinergic properties used as an antipruritic drug. It was withdrawn from the US, Canadian, and UK markets due to a risk of neutropenia. Thenalidine is an antagonist of the H1-receptor.

CNS Activity

Approval Year

1956
94
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2778
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
Sandostene

Approved Use

for the management of dermatologic and allergic conditions

Launch Date

-5.36543986E11
Doses

Doses

DosePopulationAdverse events​
25 mg 3 times / day multiple, oral (starting)
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13762246
https://pubmed.ncbi.nlm.nih.gov/13917095
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13762246
https://pubmed.ncbi.nlm.nih.gov/13917095
Disc. AE: Agranulocytosis...
AEs leading to
discontinuation/dose reduction:
Agranulocytosis (grade 5)
Sources:
https://pubmed.ncbi.nlm.nih.gov/13762246
https://pubmed.ncbi.nlm.nih.gov/13917095
AEs

AEs

AESignificanceDosePopulation
Agranulocytosis grade 5
Disc. AE
25 mg 3 times / day multiple, oral (starting)
Dose: 25 mg, 3 times / day
Route: oral
Route: multiple
Dose: 25 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/13762246
https://pubmed.ncbi.nlm.nih.gov/13917095
unhealthy, 41 years
n = 1
Health Status: unhealthy
Age Group: 41 years
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/13762246
https://pubmed.ncbi.nlm.nih.gov/13917095
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY575262
https://www.001chemical.com/chem/86-12-4
ABI Chem
AC1L1E77
Alfa Chemistry
86-12-4
https://www.alfa-chemistry.com/cas_86-12-4.htm
ChemMol
99169221
http://www.chemmol.com/chemmol/99169221.html
Chemieliva Pharmaceutical Co., Ltd
PBCM0000229
Clearsynth
CS-T-86728
https://www.clearsynth.com/en/CST86728.html
Compound Cloud
27901
Molcore
MC575262
https://www.molcore.com/product/86-12-4
MuseChem
R027335
Norris Pharm
NSZB-A064135
NovoSeek
27901
Smolecule
S545158
http://www.smolecule.com/products/s545158
THE BioTek
bt-284248
https://www.thebiotek.com/product/inhibitors/bt-284248
Toronto Research Chemicals
T343000
ZINC
ZINC000000002146
http://zinc15.docking.org/substances/ZINC000000002146
PubMed

PubMed

TitleDatePubMed
The effect of antihistaminics on cataleptogenic action of analgesics and haloperidol.
1983
Patents

Patents

EP1641446A1
8
US20040259809
3
US20140094438
6

Sample Use Guides

In Vivo Use Guide
Thenalidine was given in coated tablets, each containing 25 mg. of the active ingredient. The initial dosage was 2 tablets 4 times a day until the patient improved, or for at least one week. The maintenance dose varied between 3 and 6 tablets daily, 4 tablets daily being the average. Intravenous injection of 10 ml. of thenalidine tartrate plus calcium (50 mg. of Sandostene and 1.375 g. of calcium gluconogalactogluconate) was given in a few severe and acute cases only.
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:55:51 UTC 2023
Edited
by admin
on Sat Dec 16 16:55:51 UTC 2023
Record UNII
6U94N2D00F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THENALIDINE
INN   WHO-DD  
INN  
Official Name English
1-METHYL-4-N-2-THENYLANILINOPIPERIDINE
Common Name English
4-PIPERIDINAMINE, 1-METHYL-N-PHENYL-N-(2-THIENYLMETHYL)-
Systematic Name English
Thenalidine [WHO-DD]
Common Name English
THENOPHENOPIPERIDINE
Common Name English
thenalidine [INN]
Common Name English
THENALDINE [MI]
Common Name English
Classification Tree Code System Code
WHO-VATC QD04AA03
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
WHO-ATC R06AX53
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
WHO-VATC QR06AX53
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
WHO-ATC R06AX03
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
WHO-ATC D04AA03
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
WHO-VATC QR06AX03
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
NCI_THESAURUS C29578
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
Code System Code Type Description
MERCK INDEX
m10699
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL2105458
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
DRUG CENTRAL
2617
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
ECHA (EC/EINECS)
201-651-5
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
EVMPD
SUB10960MIG
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
DRUG BANK
DB04826
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
MESH
C005795
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
NCI_THESAURUS
C84198
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
WIKIPEDIA
THENALIDINE
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
FDA UNII
6U94N2D00F
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
EPA CompTox
DTXSID1048835
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
INN
678
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
SMS_ID
100000082725
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
PUBCHEM
27901
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
CAS
86-12-4
Created by admin on Sat Dec 16 16:55:51 UTC 2023 , Edited by admin on Sat Dec 16 16:55:51 UTC 2023
PRIMARY
Related Record Type Details
Structure of THENALIDINE MALEATE
SALT/SOLVATE -> PARENT
Structure of THENALIDINE TARTRATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of THENALIDINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966